IFNA2 and cancer: Concerning PSMs 12–15 which do not cause chromatin-bound linker histone depletion, the following data were published: thymoquinone was shown to actually decrease type I IFN signaling activity in RAW 264.7 and MCF-7 cells [64]; for ginsenoside RB1 in CRFK 157 cells after 48 h treatment, no activation of type I IFN signaling was observed [65]; apigenin was shown to influence the inhibitory effect of IFN-α on cancer cell viability, wherein said viability is mediated by 26S proteasome inhibition (however, the effect of apigenin itself on type I IFN signaling was not analyzed) [66].